Literature DB >> 20440217

Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension.

Ping Huang1, Yongsheng Xu, Ruoxin Wei, Haiping Li, Yong Tang, Jing Liu, Samuel Shao-Min Zhang, Chun Zhang.   

Abstract

PURPOSE: To compare the efficacy of topical tetrandrine (an alkaloid isolated from the Chinese medicinal herb Radix Stephania tetrandrae S) and timolol 0.5% ophthalmic solution on lowering the intraocular pressure (IOP) in ocular normotensive and hypertensive rats.
METHODS: The experiment was designed as 2 parts. In the first part, normal male Sprague-Dawley rats were divided into 4 groups followed by topical administration once of 0.1%, 0.2%, 0.3% tetrandrine, and 0.5% timolol in the right eye, 0.9% saline was administered once at the opposite eye as control. In the second part, the ocular hypertension model was induced unilaterally in the rats by a diode laser treatment. Twice daily applications of the above drugs were delivered to hypertensive eyes. The control group was administered 0.9% saline. The TonoPen XL tonometer was used to determine the IOP levels.
RESULTS: No lowering effect on IOP was detected in the normotensive rats treated with tetrandrine whereas timolol significantly reduced IOP in normotensive eyes. Both tetrandrine and timolol significantly reduced the IOP levels in the hypertensive eyes compared with the levels in the saline-treated groups. All concentrations of tetrandrine used in this study showed significant reduction of IOP in the laser-induced hypertensive eyes. Tetrandrine 0.3% had a similar efficacy as 0.5% timolol in reducing elevated IOP in ocular hypertensive eyes.
CONCLUSIONS: This study provides evidence that tetrandrine has a major effect on lowering IOP levels in the ocular hypertension rat model. The functional mechanisms of tetrandrine require further investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20440217     DOI: 10.1097/IJG.0b013e3181d7882a

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  17 in total

Review 1.  The role of microglia in the progression of glaucomatous neurodegeneration- a review.

Authors:  Hui-Lan Zeng; Jing-Ming Shi
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

2.  ROS generated by CYP450, especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes.

Authors:  Xin-ming Qi; Ling-ling Miao; Yan Cai; Li-kun Gong; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2013-07-29       Impact factor: 6.150

3.  Multilayer Coating of Tetrandrine-loaded PLGA nanoparticles: Effect of surface charges on cellular uptake rate and drug release profile.

Authors:  Rui Meng; Ke Li; Zhe Chen; Chen Shi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-02-03

Review 4.  Role of glia in optic nerve.

Authors:  Meysam Yazdankhah; Peng Shang; Sayan Ghosh; Stacey Hose; Haitao Liu; Joseph Weiss; Christopher S Fitting; Imran A Bhutto; J Samuel Zigler; Jiang Qian; José-Alain Sahel; Debasish Sinha; Nadezda A Stepicheva
Journal:  Prog Retin Eye Res       Date:  2020-08-06       Impact factor: 21.198

5.  Chitosan-coated bovine serum albumin nanoparticles for topical tetrandrine delivery in glaucoma: in vitro and in vivo assessment.

Authors:  Salma El-Sayed Radwan; Riham M El-Moslemany; Radwa A Mehanna; Eman H Thabet; Elsayeda-Zeinab A Abdelfattah; Amal El-Kamel
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

6.  Tetrandrine is a potent cell autophagy agonist via activated intracellular reactive oxygen species.

Authors:  Haiqing Wang; Ting Liu; Lu Li; Qin Wang; Chunrong Yu; Xin Liu; Wenhua Li
Journal:  Cell Biosci       Date:  2015-01-14       Impact factor: 7.133

7.  Tetrandrine protects mouse retinal ganglion cells from ischemic injury.

Authors:  Weiyi Li; Chen Yang; Jing Lu; Ping Huang; Colin J Barnstable; Chun Zhang; Samuel S Zhang
Journal:  Drug Des Devel Ther       Date:  2014-03-21       Impact factor: 4.162

8.  Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-κB and ERK signaling pathways in BV2 cells.

Authors:  Yalong Dang; Yongsheng Xu; Wentao Wu; Weiyi Li; Yanran Sun; Jing Yang; Yu Zhu; Chun Zhang
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

9.  Combination Nanotherapeutics for Dry Eye Disease Treatment in a Rabbit Model.

Authors:  Liandi Huang; Huanhuan Gao; Zhigang Wang; Yixin Zhong; Lan Hao; Zhiyu Du
Journal:  Int J Nanomedicine       Date:  2021-05-26

10.  Liquid Crystalline Nanoparticles as an Ophthalmic Delivery System for Tetrandrine: Development, Characterization, and In Vitro and In Vivo Evaluation.

Authors:  Rui Liu; Shuangshuang Wang; Shiming Fang; Jialu Wang; Jingjing Chen; Xingguo Huang; Xin He; Changxiao Liu
Journal:  Nanoscale Res Lett       Date:  2016-05-17       Impact factor: 4.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.